16980-89-5

Basic information

• Product Name: Bucladesine
• Synonyms: ibutyryl cyclic AMP sodium;Adenosine,N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate, sodiuM salt(1:1);Dibutyryl-cAMP sodium salt, >=98%;Adenosine 3?,5?-cyclic Monophosphate, N?,O;adenosine,n-(1-oxobutyl)-,cyclic3’,5’-(hydrogenphosphate)-2’-butanoate,m;bucladesinesodium;butyramide,n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-,cyclichydrogenphosphate,butyrate(ester),monosodiumsalt;dibutylcampsodiumsalt
• CAS NO: 16980-89-5
• Molecular Formula: C18H23N5NaO8P
• Molecular Weight: 491.37
• EINECS: 241-059-4
• Product Categories: Cyclic Nucleotide related
• Mol File: 16980-89-5.mol
• Article Data: 0

Chemical Properties

• Appearance: white/powder
• Storage Temp.: −20°C
• Solubility: H2O: 50 mg/mL
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month.
• Merck: 14,1463
• CAS DataBase Reference: Bucladesine(CAS DataBase Reference)
• NIST Chemistry Reference: Bucladesine(16980-89-5)
• EPA Substance Registry System: Bucladesine(16980-89-5)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 2
• RTECS: ES5055500
• F: 10-21
• Hazardous Substances Data: 16980-89-5(Hazardous Substances Data)

Usage

Description

Bucladesine sodium, also known as ACTOCIN, is a cell-permeable cyclic AMP (cAMP) analog that preferentially activates cAMP-dependent protein kinase (PKA). It is a 3',5'-cyclic purine nucleotide with cardiac stimulant and peripheral vasodilatory properties, making it useful in treating cardiac insufficiency, particularly after heart surgery. Bucladesine sodium has also been shown to induce apoptosis in vascular smooth muscle cells and acts as a Hh pathway antagonist.

Uses

Used in Pharmaceutical Industry:
Bucladesine sodium is used as a cardiac stimulant for the treatment of cardiac insufficiency, especially after heart surgery. It is also used as a vasodilator due to its peripheral vasodilatory properties.
Used in Stem Cell Research:
Bucladesine sodium is used as a medium supplement for neural crest stem cells (NCSCs) differentiation, aiding in the development and understanding of stem cell therapies.
Used in Cryopreservation:
It is used as a component of the thawing medium for cryopreserved human iPSC (induced pluripotent stem cell)-derived neurons, which is crucial for the preservation and revival of these cells for further research and potential therapeutic applications.
Used in Neuroscience Research:
Bucladesine sodium is used in serum-free Dulbecco's modified eagle's medium (DMEM) to induce astrocyte differentiation, contributing to the study of astrocyte function and development in the central nervous system.

Originator

Daiichi Seiyaku; Seishin Seiyaku (Japan)

Biochem/physiol Actions

Cell-permeable cAMP analog that activates cAMP dependent protein kinase (PKA).

References

1) Bartsch?et al.?(2003),?Bioactivatable, membrane-permeant analogs of cyclic nucleotides as biological tools for growth control of C6 glioma cells; Biol. Chem.,?384?13212) Carranza?et al.?(1998),?Protein kinase A induces recruitment of active Na+,K+-ATPase units to the plasma membrane of rat proximal convoluted tubule cells; J. Physiol.,?15?5113) Hei?et al.?(1991),?Lack of correlation between activation of cyclic AMP-dependent protein kinase and inhibition of contraction of rat vas deferens by cyclic AMP analogs; Mol. Pharmacol.,?39?2334) Imamura?et al.?(1998),?Differential expression of dystrophin isoforms and utrophin during dibutyryl-cAMP-induced morphological differentiation of rat brain astrocytes; Proc. Natl. Acad. Sci. USA,?95?61395) Xia?et al.?(2016),?Transcriptional comparison of human induced and primary midbrain dopaminergic neurons; Sci. Rep.,?6?20270

Related news

Effect of Bucladesine (cas 16980-89-5) sodium on the plasma concentrations and urinary excretion of purine bases and uridine08/08/2019

To examine whether bucladesine sodium affects the plasma concentrations of purine bases (hypoxanthine, xanthine, and uric acid) and uridine, 100 mL of physiological saline containing bucladesine sodium (6 mg/kg weight) was administered intravenously to eight healthy subjects for 1 hour after ove...detailed

Effects of pentoxifylline and H-89 on epileptogenic activity of Bucladesine (cas 16980-89-5) in pentylenetetrazol-treated mice08/05/2019

The present study shows interactive effects of pentoxifylline (PTX) as a phosphodiesterase (PDE) inhibitor, H-89 as a protein kinase A (PKA) inhibitor and bucladesine (db-cAMP) as a cAMP agonist on pentylenetetrazol (PTZ)-induced seizure in mice. Different doses of pentoxifylline (25, 50, 100 mg...detailed